共 6 条
- [4] Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint [J]. European Journal of Clinical Pharmacology, 2015, 71 : 25 - 34
- [6] Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome [J]. Journal of Thrombosis and Thrombolysis, 2011, 31 : 146 - 153